Interventional Cardiology Vascular Stents
Interventional Cardiology Vascular Stents
$599.00
The global market for vascular stents is being driven by the increasing prevalence of cardiovascular disease (CVD). CVD is the leading cause of death globally, responsible for over 17 million deaths annually.
Publisher: Biomedtracker / Meddevicetracker / Datamonitor Healthcare
- Description
- Contents
Overview
The global market for vascular stents is being driven by the increasing prevalence of cardiovascular disease (CVD). CVD is the leading cause of death globally, responsible for over 17 million deaths annually. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global vascular stents products market, which includes bare-metal stents (BMSs), drug-eluting stents (DESs), and bioresorbable vascular stents/scaffolds (BVSs). Primary research querying interventional cardiologists regarding device preferences and vascular stent utilization was leveraged in the formulation of this report’s forecasts and analyses. Global product sales are projected to expand at a compound annual growth rate (CAGR) of 6.2% during 2016-21, increasing from approximately $6,535.3m in 2016 to an estimated $8,827.1m in 2021. Countries/regions covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World segment (which combines estimated sales data for all other countries).
Table of Contents
EXECUTIVE SUMMARY …………………………………………………………………………. ES-1
i. Cardiovascular diseases overview …………………………………………. ES-1
ii. Global vascular stents market ……………………………………………….. ES-1
a. Market drivers and limiters ……………………………………… ES-3
b. Device segment insights…………………………………………. ES-4
c. Technology trends …………………………………………………. ES-5
d. Market leaders ………………………………………………………. ES-5
e. Competitive strategies ……………………………………………. ES-6
f. Emerging competition …………………………………………….. ES-6
iii. Methodology ……………………………………………………………………….. ES-7
Exhibit ES-1: Vascular stents global market forecast, 2016-21 ………………………. ES-2
Exhibit ES-2: Global vascular stents market, share by country/region, 2016 ……. ES-3
Exhibit ES-3: Drivers and limiters of growth of the vascular stents market ………. ES-4
1. CARDIOVASCULAR DISEASES OVERVIEW …………………………………….. 1-1
1.1 Acute coronary syndrome ………………………………………………………… 1-3
1.1.1 Atherosclerosis ………………………………………………………… 1-4
1.1.2 Angina pectoris ………………………………………………………… 1-5
1.1.3 Myocardial infarction ………………………………………………… 1-6
1.1.4 Diagnosis and treatment………………………………………….. 1-10
1.2 Hypertension ……………………………………………………………………….. 1-10
1.3 Peripheral vascular disease …………………………………………………… 1-13
1.3.1 Critical limb ischemia ………………………………………………. 1-14
1.3.2 Aneurysm ……………………………………………………………… 1-14
1.3.3 Deep vein thrombosis/pulmonary embolism ……………….. 1-15
1.3.4 Diagnosis and treatment………………………………………….. 1-17
1.4 Cerebrovascular disease ……………………………………………………….. 1-18
1.4.1 Diagnosis and treatment………………………………………….. 1-21
1.5 Bibliography …………………………………………………………………………. 1-22
Exhibit 1-1: Estimated mortality due to ischemic heart disease and cerebrovascular disease, select countries ………………………………….. 1-1
Exhibit 1-2: Top 10 countries with the highest CVD death rates……………………… 1-2
Exhibit 1-3: Estimated incident cases for acute coronary syndrome, select countries ……………………………………………………………………… 1-4
Exhibit 1-4: Age-standardized incidence (000s) of angina pectoris, select regions ………………………………………………………………………… 1-6
Exhibit 1-5: Clinical classification of acute myocardial infarction ……………………. 1-7
Exhibit 1-6: Age-standardized incidence (000s) of acute myocardial infarction, select regions ………………………………………………………….. 1-9
Exhibit 1-7: Estimated incident cases of myocardial infarction, select countries .. 1-9
Exhibit 1-8: Estimated prevalent cases of hypertension, select countries ………. 1-12
Exhibit 1-9: Mortality attributable to hypertensive diseases, select countries ….. 1-12
Exhibit 1-10: Estimated incident cases of DVT, select countries …………………….. 1-16
Exhibit 1-11: Estimated incident cases of PE, select countries ………………………. 1-17
Exhibit 1-12: Estimated incident cases of stroke, select countries ………………….. 1-20
Exhibit 1-13: Estimated prevalent cases of stroke, select countries ………………… 1-20
2. VASCULAR STENT PRODUCTS ……………………………………………………… 2-1
2.1 Vascular stent products …………………………………………………………… 2-2
2.2 Vascular stents in development ………………………………………………… 2-9
2.3 Trends in vascular stent innovation …………………………………………. 2-12
2.4 Alternatives to vascular stent implantation ……………………………….. 2-13
2.5 Bibliography …………………………………………………………………………. 2-15
Exhibit 2-1: Advantages and disadvantages of stenting ………………………………… 2-2
Exhibit 2-2: Images of select vascular stents ………………………………………………. 2-3
Exhibit 2-3: Selected bare-metal stents and manufacturers …………………………… 2-4
Exhibit 2-4: Selected drug-eluting stents and manufacturers …………………………. 2-6
Exhibit 2-5: Advantages and disadvantages of BVSs ……………………………………. 2-7
Exhibit 2-6: Selected BVSs and manufacturers ……………………………………………. 2-9
Exhibit 2-7: Current clinical trials investigating stent devices ……………………….. 2-10
Exhibit 2-8: Selected drug-eluting BVSs in development …………………………….. 2-11
Exhibit 2-9: Information on selected non-drug-eluting BVSs in development ….. 2-12
3. VASCULAR STENTS MARKET ………………………………………………………… 3-1
3.1 Global market insights …………………………………………………………….. 3-1
3.1.1 Market value ……………………………………………………………. 3-2
3.1.2 Technology trends ……………………………………………………. 3-7
3.1.3 Market drivers and limiters ………………………………………. 3-10
3.1.4 Vascular stents overview …………………………………………. 3-13
3.1.5 Market leaders ……………………………………………………….. 3-15
3.1.6 Competitive strategies …………………………………………….. 3-16
3.1.7 Emerging competition ……………………………………………… 3-16
3.2 Global competitors ………………………………………………………………… 3-17
3.2.1 Bare-metal stents …………………………………………………… 3-17
3.2.2 Drug-eluting stents …………………………………………………. 3-18
3.3 Market forecast …………………………………………………………………….. 3-19
3.3.1 Market forecast: US ………………………………………………… 3-20
3.3.2 Market forecast: five major EU markets ……………………… 3-30
3.3.3 Market forecast: Japan ……………………………………………. 3-44
3.3.4 Market forecast: rest of the world ……………………………… 3-52
3.4 Bibliography …………………………………………………………………………. 3-63
Exhibit 3-1: Vascular stents, global market forecast, 2016-21 ………………………… 3-3
Exhibit 3-2: Vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………… 3-4
Exhibit 3-3: Global vascular stents market, share by country/region, 2016 ………. 3-6
Exhibit 3-4: Global vascular stent sales combined market forecast, by country/region ($m), 2016-21 …………………………………………………… 3-8
Exhibit 3-5: Drivers and limiters of growth of the vascular stents market ……….. 3-13
Exhibit 3-6: Average sale prices of vascular stents in 2017 …………………………. 3-15
Exhibit 3-7: Global bare-metal stents market, share by supplier, 2016 ………….. 3-18
Exhibit 3-8: Global drug-eluting stents market, share by supplier, 2016 …………. 3-19
Exhibit 3-9: US vascular stent implantation, procedure volumes forecast (000s), 2016-21 ……………………………………………………………………. 3-22
Exhibit 3-10: US vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-24
Exhibit 3-11: US bare-metal stents market forecast, by type ($m), 2016-21 …….. 3-26
Exhibit 3-12: US bare-metal stents market, share by supplier, 2016 ……………….. 3-27
Exhibit 3-13: US drug-eluting stents market forecast, by type ($m), 2016-21 …… 3-29
Exhibit 3-14: US drug-eluting stents market, share by supplier, 2016 ……………… 3-30
Exhibit 3-15: 5EU coronary vascular stent implantation, procedure volumes forecast, by country (000s), 2016-21 ………………………………………. 3-33
Exhibit 3-16: 5EU peripheral vascular stent implantation, procedure volumes forecast, by country (000s), 2016-21 ………………………………………. 3-35
Exhibit 3-17: 5EU vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-38
Exhibit 3-18: 5EU bare-metal stents market forecast, by type ($m), 2016-21 …… 3-40
Exhibit 3-19: 5EU bare-metal stents market, share by supplier, 2016 ……………… 3-41
Exhibit 3-20: 5EU drug-eluting stents market forecast, by type ($m), 2016-21 …. 3-43
Exhibit 3-21: 5EU drug-eluting stents market, share by supplier, 2016 ……………. 3-44
Exhibit 3-22: Japan vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-45
Exhibit 3-23: Japan coronary stent implantation, procedure volumes forecast (000s), 2016-21 ……………………………………………………………………. 3-47
Exhibit 3-24: Japan bare-metal stents market forecast, by type ($m), 2016-21 … 3-49
Exhibit 3-25: Japan bare-metal stents market, share by supplier, 2016 …………… 3-50
Exhibit 3-26: Japan drug-eluting stents market forecast, by type ($m), 2016-21 .. 3-51
Exhibit 3-27: Japan drug-eluting stents market, share by supplier, 2016 …………. 3-52
Exhibit 3-28: RoW vascular stent sales combined market forecast, by product segment ($m), 2016-21 …………………………………………………………. 3-53
Exhibit 3-29: RoW bare-metal stents market forecast, by type ($m) 2016-21 …… 3-58
Exhibit 3-30: RoW bare-metal stents market, share by supplier, 2016 …………….. 3-59
Exhibit 3-31: RoW drug-eluting stents market forecast, by type ($m), 2016-21 … 3-60
Exhibit 3-32: RoW drug-eluting stents market, share by supplier, 2016 …………… 3-62
APPENDIX: COMPANY LISTING ……………………………………………………………… A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Latest Trends in Orphan Drug Pricing and Reimbursement 
Sign up to the